公开(公告)号：US20250011307A1

公开(公告)日：2025-01-09

申请号：US18687609

申请日：2022-08-30

Applicant: Novartis AG

Inventor： Runyan LI ,  Bo LIU ,  Michael MUTZ ,  Lina YUAN ,  Yingcong ZHOU

IPC: C07D405/04 ,  A61K31/343 ,  A61K31/4025 ,  C07D307/81

Abstract: The present invention generally relates to crystalline polymorphic forms of the biaryl YAP/TAZ-TEAD protein-protein interaction inhibitors 4-((2S,4S)-5-Chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-5-fluoro-6-(2-hydroxyethoxy)-N-methylnicotinamide and 2-((2S,3S,4S)-5-Chloro-6-fluoro-3-methyl-2-((methylamino)methyl)-2-phenyl-2,3-dihydrobenzofuran-4-yl)-3-fluoro-4-methoxybenzamide and salts thereof, as well as methods of using the forms in the treatment of cancer.

公开(公告)号：US20210253534A1

公开(公告)日：2021-08-19

申请号：US17236596

申请日：2021-04-21

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Runyan LI ,  Valentina MOLTENI ,  John NELSON ,  Jason Thomas ROLAND ,  Paul Vincent RUCKER ,  David Charles TULLY ,  Xiaoyang WANG ,  Liladhar Murlidhar WAYKOLE ,  Yubo ZHANG ,  Bo ZHOU

IPC: C07D231/54 ,  C07D471/04 ,  C07D491/052 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/4745 ,  C07D471/06

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US20190062283A1

公开(公告)日：2019-02-28

申请号：US16056881

申请日：2018-08-07

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Runyan LI ,  Valentina Molteni ,  John Nelson ,  Jason Thomas Roland ,  Paul Vincent Rucker ,  David Charles Tully ,  Xiaoyang WANG ,  Liladhar Murlidhar WAYKOLE ,  Yubo ZHANG ,  Bo ZHOU

IPC: C07D231/54 ,  A61K31/4745 ,  A61K31/4439 ,  A61K31/4162 ,  C07D471/04 ,  C07D471/06 ,  C07D491/052 ,  A61K31/416

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US20200247757A1

公开(公告)日：2020-08-06

申请号：US16854762

申请日：2020-04-21

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Runyan LI ,  Valentina MOLTENI ,  John NELSON ,  Jason Thomas ROLAND ,  Paul Vincent RUCKER ,  David Charles TULLY ,  Xiaoyang WANG ,  Liladhar Murlidhar WAYKOLE ,  Yubo ZHANG ,  Bo ZHOU

IPC: C07D231/54 ,  C07D471/04 ,  C07D491/052 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/4745 ,  C07D471/06

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).